San Diego, CA -- (SBWIRE) -- 03/23/2018 -- An investigation was announced for investors, who currently hold NASDAQ: CGNT shares, concerning whether the takeover of Cogentix Medical, Inc. by Laborie Medical Technologies is unfair.

Investors who purchased shares of Cogentix Medical, Inc. (NASDAQ: CGNT) and currently hold any of those NASDAQ: CGNT shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm concerns whether certain officers and directors of Cogentix Medical, Inc. breached their fiduciary duties owed to NASDAQ: CGNT investors in connection with the proposed acquisition.

On March 12, 2018, Cogentix Medical, Inc. (NASDAQ: CGNT), announced that it has entered into a definitive merger agreement, under which Laborie Medical Technologies (LABORIE) will acquire all of the outstanding shares of Cogentix Medical for a total consideration of approximately $239 million. Under the terms of the definitive merger agreement, LABORIE (through its wholly-owned subsidiaries LM US Parent, Inc. (Parent) and Camden Merger Sub, Inc. (Merger Sub) will commence a tender offer for all outstanding shares of Cogentix Medical common stock for $3.85 per share in cash.

However, given that at least one analyst has set the high target price for NASDAQ: CGNT shares at $5.00 per share, the investigation concerns whether the offer is unfair to NASDAQ: CGNT stockholders.

In addition, given that Accelmed Growth Partners LP and Mr. Lewis Pell, who collectively beneficially own shares representing approximately 60% of Cogentix Medical's outstanding common stock, have already entered into tender and support agreements in favor of Parent and Merger Sub, pursuant to which those stockholders, among other things, will agree to tender all of their shares of Cogentix Medical common stock beneficially owned by them to Merger Sub in response to the tender offer, as well as restrictive covenant agreements in favor of Parent and Merger Sub, the investigation concerns whether the Cogentix Medical Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders' best interests in connection with the proposed sale.

On March 22, 2018, NASDAQ: CGNT shares closed at $3.83 per share.

Those who are current investors in Cogentix Medical, Inc. (NASDAQ: CGNT) shares have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com